Jan 13, 2022 / 02:00PM GMT
Unidentified Analyst -
Good morning, and thank you for joining us today. My name is [Fauci Kash], and I'm an analyst at JPMorgan Selfcare Group. Before we get started, I just wanted to note that there will be no Q&A for the session. And with that, I'll pass it over to our speakers, RA Session, President, CEO and Founder of Taysha Gene Therapies; and Suyash Prasad, Medical Officer and Head of R&D.
R. A. Session - Taysha Gene Therapies, Inc. - Founder, President, CEO & Director
Thanks, [Fauci]. Good morning, everyone. Thank you, guys, for having us this morning. I'm happy to be presenting an initial overview of our story. I'll just start with some forward-looking statements here. And here's a summary of the company really why we're so excited about what lies ahead for 2022, just starting with a couple of near-term value inflection points. We'll be reporting long-term durability and long-term safety data on our high-dose cohorts and our other therapeutic doses, from our lead program, TSHA-120 giant axonal neuropathy later this month.
We'll also be
Taysha Gene Therapies Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers